Skip to main content

Advertisement

SpringerLink
Log in

Genetic profiling as a clinical tool in advanced parathyroid carcinoma

  • Original Article – Cancer Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Context

Parathyroid carcinoma (PC) is a rare endocrine malignancy with no approved systemic therapies for unresectable locally invasive or distant metastatic disease. Understanding the molecular changes in advanced PC can provide better understanding of this disease and potentially help directing targeted therapy.

Objective

To evaluate tumor-specific genetic changes using next-generation sequencing (NGS) panels.

Design

All patients with advanced PC were tested for hot-spot panels using NGS panels including a 50-gene panel, a 409-gene panel if the standard 50-gene panel (Ion Torrent, Life Technology) was negative or a FoundationOne panel.

Setting

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Patients or other participants

11 patients with advanced PC were selected to undergo molecular testing.

Main outcome measure(s)

Genetic profiles of advanced PC.

Results

Among the 11 patients, 4 patients had the 50-gene panel only, 6 had 409-gene panel after a negative 50-gene panel and 1 had FoundationOne. One patient who had 50-gene panel only also had his metastatic site (esophagus) of his tumor tested with FoundationOne. The most common mutations identified were in the PI3 K (PIK3CA, TSC1 and ATM) (4/11 patients) and TP53 (3/11) pathways. Genes not previously reported to be mutated in PC included: SDHA, TERT promoter and DICER1. Actionable mutations were found in 54% (6/11) of the patients.

Conclusions

Mutational profiling using NGS panels in advanced PC has yielded important potentially targetable genetic alterations. Larger studies are needed to identify commonly mutated genes in advanced PC patients. Development of novel therapies targeting these cellular pathways should be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Agha A, Carpenter R, Bhattacharya S, Edmonson SJ, Carlsen E, Monson JP (2007) Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: two case reports of an unrecognised entity. J Endocrinol Invest 30(2):145–149

    Article  CAS  PubMed  Google Scholar 

  • Bihani T, Ezell SA, Ladd B, Grosskurth SE, Mazzola AM, Pietras M, Reimer C, Zinda M, Fawell S, D’Cruz CM (2015) Resistance to everolimus driven by epigenetic regulation of MYC in ER+breast cancers. Oncotarget 6(4):2407–2420

    Article  PubMed  Google Scholar 

  • Burchett KM, Yan Y, Ouellette MM (2014) Telomerase inhibitor imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS One 9(1):e85155

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Burnichon N, Briere JJ, Libe R, Vescovo L, Riviere J, Tissier F, Jouanno E, Jeunemaitre X, Benit P, Tzagoloff A, Rustin P, Bertherat J, Favier J, Gimenez-Roqueplo AP (2010) SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19(15):3011–3020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM Jr, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R (2004) Parathyroid carcinoma: a 22-year experience. Head Neck 26(8):716–726

    Article  PubMed  Google Scholar 

  • Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655–1657

    Article  CAS  PubMed  Google Scholar 

  • Celeghin A, Giunco S, Freguja R, Zangrossi M, Nalio S, Dolcetti R, De Rossi A (2016) Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells. Cell Death Dis 7(12):e2562

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cetani F, Pardi E, Viacava P, Pollina GD, Fanelli G, Picone A, Borsari S, Gazzerro E, Miccoli P, Berti P, Pinchera A, Marcocci C (2004) A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) 60(1):99–106

    Article  CAS  Google Scholar 

  • Cetani F, Pardi E, Marcocci C (2016) Update on parathyroid carcinoma. J Endocrinol Invest 39(6):595–606

    Article  CAS  PubMed  Google Scholar 

  • Christakis I, Busaidy NL, Cote GJ, Williams MD, Hyde SM, Silva Figueroa AM, Kwatampora LJ, Clarke CN, Qiu W, Lee JE, Perrier ND (2016) Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; a clinico-pathologic challenge The MD Anderson case series and review of the literature. Int J Surg 31:10–16

    Article  PubMed  Google Scholar 

  • Christakis I, Silva AM, Williams MD, Garden A, Grubbs EG, Busaidy NL, Lee JE, Perrier ND, Zafereo M (2017) Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: the MD Anderson experience of 35 years. Pract Radiat Oncol 7(6):e463–e470

    Article  PubMed  Google Scholar 

  • Cryns VL, Rubio MP, Thor AD, Louis DN, Arnold A (1994) p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 78(6):1320–1324

    CAS  PubMed  Google Scholar 

  • Curatolo P, Maria BL (2013) Tuberous sclerosis. Handb Clin Neurol 111:323–331

    Article  CAS  PubMed  Google Scholar 

  • DeLellis R (2004) Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon, France

    Google Scholar 

  • Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Hess JM, Gimelbrant AA, Beroukhim R, Lawrence MS, Getz G, Lane AA (2017) Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet 49(1):10–16

    Article  CAS  PubMed  Google Scholar 

  • Dwight T, Mann K, Benn DE, Robinson BG, McKelvie P, Gill AJ, Winship I, Clifton-Bligh RJ (2013a) Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab 98(6):E1103–E1108

    Article  CAS  PubMed  Google Scholar 

  • Dwight T, Benn DE, Clarkson A, Vilain R, Lipton L, Robinson BG, Clifton-Bligh RJ, Gill AJ (2013b) Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol 37(2):226–233

    Article  PubMed  Google Scholar 

  • Foulkes WD, Priest JR, Duchaine TF (2014) DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer 14(10):662–672

    Article  CAS  PubMed  Google Scholar 

  • FoundationOne. https://assets.ctfassets.net/vhribv12lmne/6YRrchSINOeSu48YwuesoY/0c3651c8421fa3647ccede76de9dce61/MKT-0054-02_F1_TechSpecs_digital.pdf. [3/27/2018]

  • Frank-Raue K, Haag C, Schulze E, Keuser R, Raue F, Dralle H, Lorenz K (2011) CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum. Eur J Endocrinol 165(3):477–483

    Article  CAS  PubMed  Google Scholar 

  • Gotley DC, Reeder JA, Fawcett J, Walsh MD, Bates P, Simmons DL, Antalis TM (1996) The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases. Oncogene 13(4):787–795

    CAS  PubMed  Google Scholar 

  • Guo Y, Chekaluk Y, Zhang J, Du J, Gray NS, Wu CL, Kwiatkowski DJ (2013) TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. J Pathol 230(1):17–27

    Article  CAS  PubMed  Google Scholar 

  • Haglund F, Juhlin CC, Brown T, Ghaderi M, Liu T, Stenman A, Dinets A, Prasad M, Korah R, Xu D, Carling T, Larsson C (2015) TERT promoter mutations are rare in parathyroid tumors. Endocr Relat Cancer 22(3):L9

    Article  CAS  PubMed  Google Scholar 

  • Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, Voss MH, Motzer RJ, Coleman JA, Cheng EH, Russo P, Hsieh JJ (2013) Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 63(5):848–854

    Article  PubMed  Google Scholar 

  • Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi T, Knowles MA (1999) Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18(16):2657–2661

    Article  CAS  PubMed  Google Scholar 

  • Hsieh JJ, Chen D, Wang PI, Marker M, Redzematovic A, Chen YB, Selcuklu SD, Weinhold N, Bouvier N, Huberman KH, Bhanot U, Chevinsky MS, Patel P, Pinciroli P, Won HH, You D, Viale A, Lee W, Hakimi AA, Berger MF, Socci ND, Cheng EH, Knox J, Voss MH, Voi M, Motzer RJ (2017) Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma. Eur Urol 71(3):405–414

    Article  CAS  PubMed  Google Scholar 

  • https://www.thermofisher.com/order/catalog/product/4475346. [cited 2018 3/23]

  • https://www.thermofisher.com/order/catalog/product/4477685. [cited 2018 3/23]

  • Huang J, Manning BD (2008) The TSC1–TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412(2):179–190

    Article  CAS  PubMed  Google Scholar 

  • Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, Pochanard P, Yang D, Ruddy D, Liu M, Derti A, Balak MN, Palmer MR, Wang Y, Lee BH, Sellami D, Zhu AX, Schlegel R, Huang A (2015) Loss of tuberous sclerosis complex 2 (TSC2) Is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus. Mol Cancer Ther 14(5):1224–1235

    Article  CAS  PubMed  Google Scholar 

  • Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338(6104):221

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jackson MA, Rich TA, Hu MI, Perrier ND, Waguespack SG (1993) CDC73-Related Disorders. In: Adam MP et al (eds) GeneReviews((R)). University of Washington, Seattle

    Google Scholar 

  • Ji X, Jin S, Qu X, Li K, Wang H, He H, Guo F, Dong L (2015) Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression. BMC Cancer 15:801

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kang H, Schubert AD, Ladenson P, Ball DW, Chung J, Schrock AB, Ross JS, Miller VA, Stephens PJ, Ali SM (2017) Comprehensive genomic profiling of parathyroid carcinoma. J Clin Oncol 35(15 suppl):6088

    Article  Google Scholar 

  • Kasaian K, Wiseman SM, Thiessen N, Mungall KL, Corbett RD, Qian JQ, Nip KM, He A, Tse K, Chuah E, Varhol RJ, Pandoh P, McDonald H, Zeng T, Tam A, Schein J, Birol I, Mungall AJ, Moore RA, Zhao Y, Hirst M, Marra MA, Walker BA, Jones SJ (2013) Complete genomic landscape of a recurring sporadic parathyroid carcinoma. J Pathol 230(3):249–260

    Article  CAS  PubMed  Google Scholar 

  • Khoo KH, Verma CS, Lane DP (2014) Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 13(3):217–236

    Article  CAS  PubMed  Google Scholar 

  • Knudson AG (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1(2):157–162

    Article  CAS  PubMed  Google Scholar 

  • Kopetz S, Litzenburger B, Kinyua W, Sajan B, Subbiah V, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw KR, Lee JJ, Broaddus R (2015) Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. J Clin Oncol 33(15 suppl):3608

    Article  Google Scholar 

  • Lazaris AC, Tseleni-Balafouta S, Papathomas T, Brousalis T, Thomopoulou G, Agrogiannis G, Patsouris ES (2006) Immunohistochemical investigation of angiogenic factors in parathyroid proliferative lesions. Eur J Endocrinol 154(6):827–833

    Article  CAS  PubMed  Google Scholar 

  • Le Tourneau C, Raymond E, Faivre S (2007) Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag 3(2):341–348

    Article  PubMed  PubMed Central  Google Scholar 

  • Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93(8):3106–3116

    Article  CAS  PubMed  Google Scholar 

  • Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (2008) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14(17):5459–5465

    Article  CAS  PubMed  Google Scholar 

  • Mosrati MA, Malmstrom A, Lysiak M, Krysztofiak A, Hallbeck M, Milos P, Hallbeck AL, Bratthall C, Strandeus M, Stenmark-Askmalm M, Soderkvist P (2015) TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 6(18):16663–16673

    Article  PubMed  PubMed Central  Google Scholar 

  • NEXAVAR Prescribing Information (2018) Bayer HealthCare Pharmaceuticals, Inc; Whippany, NJ

  • Owonikoko TK, Khuri FR (2013) Targeting the PI3 K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book 33:e395

    Article  Google Scholar 

  • Pandya C, Uzilov AV, Bellizzi J, Lau CY, Moe AS, Strahl M, Hamou W, Newman LC, Fink MY, Antipin Y, Yu W, Stevenson M, Cavaco BM, Teh BT, Thakker RV, Morreau H, Schadt EE, Sebra R, Li SD, Arnold A, Chen R (2017) Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight 2(6):e92061

    Article  PubMed  PubMed Central  Google Scholar 

  • Paolicchi E, Crea F, Farrar WL, Green JE, Danesi R (2013) Histone lysine demethylases in breast cancer. Crit Rev Oncol Hematol 86(2):97–103

    Article  PubMed  Google Scholar 

  • Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, Pooley KA, Pritchard AL, Tiffen JC, Petljak M, Palmer JM, Symmons J, Johansson P, Stark MS, Gartside MG, Snowden H, Montgomery GW, Martin NG, Liu JZ, Choi J, Makowski M, Brown KM, Dunning AM, Keane TM, Lopez-Otin C, Gruis NA, Hayward NK, Bishop DT, Newton-Bishop JA, Adams DJ (2014) POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 46(5):478–481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N, Bailey-Wilson J, Trent J, Carpten J, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J (2002) Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 70(5):1299–1304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P (2000) Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 97(6):2773–2778

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schulte KM, Talat N (2012) Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol 8(10):612–622

    Article  CAS  PubMed  Google Scholar 

  • Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349(18):1722–1729

    Article  CAS  PubMed  Google Scholar 

  • Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21(1):99–102

    Article  CAS  PubMed  Google Scholar 

  • Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD, Luthra R (2013) Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 15(5):607–622

    Article  CAS  PubMed  Google Scholar 

  • Singh RR, Patel KP, Routbort MJ, Aldape K, Lu X, Manekia J, Abraham R, Reddy NG, Barkoh BA, Veliyathu J, Medeiros LJ, Luthra R (2014) Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer 111(10):2014–2023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stracquadanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, Zeron-Medina J, Castro-Giner F, Tomlinson IP, Goding CR, Cygan KJ, Fairbrother WG, Thomas LF, Saetrom P, Gemignani F, Landi S, Schuster-Bockler B, Bell DA, Bond GL (2016) The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat Rev Cancer 16(4):251–265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185

    Article  PubMed  CAS  Google Scholar 

  • Wu J, Ellison J, Salido E, Yen P, Mohandas T, Shapiro LJ (1994) Isolation and characterization of XE169, a novel human gene that escapes X-inactivation. Hum Mol Genet 3(1):153–160

    Article  CAS  PubMed  Google Scholar 

  • Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J (2014) BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32(25):2718–2726

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yu W, McPherson JR, Stevenson M, van Eijk R, Heng HL, Newey P, Gan A, Ruano D, Huang D, Poon SL, Ong CK, van Wezel T, Cavaco B, Rozen SG, Tan P, Teh BT, Thakker RV, Morreau H (2015) Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. J Clin Endocrinol Metab 100(2):E360–E364

    Article  CAS  PubMed  Google Scholar 

  • Yuan TL, Cantley LC (2008) PI3 K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497–5510

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We wish to thank Mrs. Jennifer Jordan and Mr. Len Jordan for their generous contributions that made this study possible. We thank Bryan Tutt from the Scientific Publications Department at MD Anderson Cancer Center for editing our manuscript.

Funding

Supported by the NIH/NCI under award number P30CA016672 and philanthropic donation from patients

Author information

Author notes

  1. Merve Kutahyalioglu and Ha T. Nguyen are co-first authors.

Authors and Affiliations

  1. Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street Unit 1461, Houston, TX, 77030, USA

    Merve Kutahyalioglu, Ha T. Nguyen, Lily Kwatampora, Eiman Ibrahim, Steven G. Waguespack, Maria E. Cabanillas, Camilo Jimenez, Mimi I. Hu, Steven I. Sherman, Ramona Dadu, Kacey Wanland & Naifa L. Busaidy

  2. Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Callisia Clarke, Angelica Silva & Nancy Perrier

  3. Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Scott Kopetz

  4. Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Russell Broaddus & Michelle Williams

  5. Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Mark Zafereo

Authors
  1. Merve Kutahyalioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ha T. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lily Kwatampora
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Callisia Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Angelica Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eiman Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Steven G. Waguespack
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria E. Cabanillas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Camilo Jimenez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mimi I. Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Steven I. Sherman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Scott Kopetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Russell Broaddus
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ramona Dadu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kacey Wanland
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Michelle Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Mark Zafereo
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Nancy Perrier
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Naifa L. Busaidy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naifa L. Busaidy.

Ethics declarations

Conflict of interest

NLB has received grant funding from Novartis and Bayer and consulting fees from Eisai. MEC has received grant funding from Eisai. MK, HTN, LK, CC, AS, EI, SGW, CJ, MH, SS, SK, RB, RD, KW, MW, MZ, NP: nothing to disclose

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kutahyalioglu, M., Nguyen, H.T., Kwatampora, L. et al. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145, 1977–1986 (2019). https://doi.org/10.1007/s00432-019-02945-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-019-02945-9

Keywords

Search

Navigation